Six-month Randomized, Placebo-controlled, Double-blind, Pilot Clinical Trial Of Curcumin In Patients With Alzheimer Disease
Notes for this study:
|Number of Subjects
In a double-blind 6 month controlled trial conducted in 50+ year olds with memory decline, investigating 1 or 4g curcumin daily (against placebo).
Serum amyloid-beta pigmentation and isoprostanes did not differ between groups, although a non-significant trend was shown for serum levels of AB to rise.
As measured by the MMSE, a rising of the rating scale in placebo by 1.3 points (indicating a decline of cognitive capacity) seems to have been mitigated in experimental groups, although not reversed.